SIRO Clinpharm and Peregrine Pharmaceuticals Highlight Successful Collaboration

MUMBAI, India, October 11, 2011 /PRNewswire/ --

SIRO Clinpharm a Clinical Research Organization (CRO) with presence in Asia, Europe and U.S. highlights its successful collaboration with Peregrine Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections.

SIRO has been associated with Peregrine for the past several years and has completed a Phase II trial in India involving recurrent glioblastoma multiforme (GBM) patients treated with Cotara, an investigational radiopharmaceutical product. SIRO was assigned to identify and manage the Indian arm of the trial comprising multiple sites across the country, and was instrumental in enrolling the majority of patients.  

Mr. Joseph S. Shan, M.P.H., Vice President of Clinical and Regulatory Affairs, of Peregrine Pharmaceuticals said, "We are pleased to be associated with SIRO Clinpharm, as SIRO brings expertise in the field of clinical research and has connected us with investigators experienced in conducting GBM trials. SIRO has the capability to execute complex clinical studies and they have provided us with experienced investigators, state-of-the-art research facilities, and quality monitoring which are critical elements for well-controlled clinical trials."

Dr. Ajit Nair, President, Global Operations, SIRO Clinpharm said, "It is indeed a pleasure to be associated with Peregrine which has entrusted faith in us as a company. Treating recurrent GBM is extremely challenging, but with proper planning and meticulous execution by the SIRO Project Team and Project Manager, we could achieve our goal. This trial has reaffirmed the fact that investigators in India are not only capable of handling complex clinical trials, but also comply with stringent regulatory international standards."

SIRO has effectively executed more than 50 trials in oncology in last 5 years, being one of the key therapeutic areas apart from endocrinology, cardiovascular, respiratory system and CNS. "We have successfully managed projects in these therapeutic areas in various countries involving European and Asian sites," said Dr. Nair.

With more than 70 studies in phase II and over 120 studies in phase III, SIRO has managed more than 300 clinical operations studies. Currently, the company is working with more than 3000 sites across geographies where over 70,000 clinical trial subjects have been recruited.

About SIRO:

SIRO Clinpharm Private Limited (SIRO) is among one of the leading global Clinical Research Organizations (CROs), offering full scope services, conducting clinical trials in the Pharmaceutical, Biotechnology and Medical Devices sectors in compliance with International Standards. SIRO is one of the first CROs founded in India, which caters to the needs of pharmaceutical companies across the world. The company has offices in India, Malaysia, USA, Israel and in Europe at Germany, Romania, Estonia, Greece, Czech Republic and Spain.

For more information please visit our website- http://www.siroclinpharm.com

Contact: Aniruddha Patwardhan, Email Id - [email protected] , Contact No - +91-22-2584-8000

SOURCE SIRO Clinpharm

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED